DTT106

Phase 3Small molecule

EEMS

DTT106 is one of 28 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaNot yet recruiting

Benign Prostatic HyperplasiaPhase 3

Not yet recruiting

Competition

Competitive Landscape

35 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

27 2

Cialis

Eli Lilly

Approved

19 3

Rapaflo

AbbVie

Approved

10 4

Myrbetriq

Astellas

Approved

2 5

Avodart

Akero Therapeutics

Approved

9 6

Vesicare

Astellas

Approved

1 7

Uroxatral

AAdvanz Pharma

Approved

6 8

Taxol

Propecia

4 10

Minipress

Pfizer

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Benign Prostatic Hyperplasia

NCT06264414

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Not yet recruiting·EEMS·Phase 3·NCT06264414·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DTT106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DTT106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DTT106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

DTT106

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News